Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
New Haven, Connecticut. August 5, 2008 — Rib-X Pharmaceuticals, Inc.,
a development stage company focused on the discovery and development of novel antibiotics
for the treatment of antibiotic-resistant infections, announced today that company representatives
are giving three presentations at two conferences this week.
Additionally, Graham Johnson, Ph.D, Chief Research Officer of Rib-X will give a presentation in the "Late-Breaking Topics" session, Thursday, August 7. The title of the talk is "Discovery and Clinical Development of radezolid (RX-1741), a Designer Oxazolidinone" and will highlight the Company's proprietary discovery process utilizing structural, computational and chemistry approaches; radezolid has distinct physical properties as well as a promising efficacy and safety profile.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
Gordon Research Conference on Medicinal Chemistry, August 3 — 8
Ashoke Bhattacharjee, Ph.D, Senior Scientist, presented at the Gordon Research Conference on
Medicinal Chemistry this week at Colby Sawyer College, New London, New Hampshire. Dr. Bhattacharjee
introduced Rib-X's enhanced macrolide program in a poster session titled, "Structure Based Drug
Design Targeting Infectious Disease: Overcoming Resistance and Extending the Antimicrobial Spectrum
of Macrolide Antibiotics." In his presentation on August 3 and 4, Dr. Bhattacharjee
highlighted how the combination of structural insights from X-ray crystallographic studies of
known and new antibiotics bound to the bacterial 50S ribosomal subunit with data driven
computational chemistry tools allows for a fresh look at macrolide antibiotics.
Additionally, Graham Johnson, Ph.D, Chief Research Officer of Rib-X will give a presentation in the "Late-Breaking Topics" session, Thursday, August 7. The title of the talk is "Discovery and Clinical Development of radezolid (RX-1741), a Designer Oxazolidinone" and will highlight the Company's proprietary discovery process utilizing structural, computational and chemistry approaches; radezolid has distinct physical properties as well as a promising efficacy and safety profile.
Drug Discovery & Development of Innovative Therapeutics World Conference, August 4 — 7
Joseph DeVito, Ph.D, Associate Director, Discovery Biology, Rib-X Pharmaceuticals, Inc., is presenting
Rib-X's Rχ-04 program at IBC's 12th Annual Drug Discovery & Development of Innovative Therapeutics
World Conference Technology Conference today at 11:00 AM ET at The World Trade Center Boston and
Seaport Hotel, Boston, Massachusetts. Dr. DeVito will highlight RX-04 in a presentation titled "Using
Structure Based Discovery to Define Novel Antibiotics Targeting the 50S Ribosomal Subunit." Rχ-04
is Rib-X's
de novo
design of three completely new series of antibacterials showing promising activity against serious
multidrug resistant Gram-negative pathogens, including,
Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Klebsiella pneumoniae, Acinetobacter baumanii
and
Escherichia coli.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
| Public Relations |
|---|
|
Kari Watson
MacDougall BioMedical Communications 781-235-3060 kari@macbiocom.com |
| Investor Relations |
|
Sarah Cavanaugh
MacDougall BioMedical Communications 781-235-3060 scavanaugh@macbiocom.com |